Entera Bio (ENTX) Non-Current Assets (2017 - 2026)
Entera Bio (ENTX) recorded quarterly Non-Current Assets of $636000.0 in Q1 2026, down 8.49% on a QoQ basis from $695000.0 in Q4 2025, and up 66.49% year-over-year from $382000.0 in Q1 2025.
Entera Bio (ENTX) Non-Current Assets (2017 - 2026) Analysis & Trends
Entera Bio has disclosed Non-Current Assets across 9 years of filings, most recently posting $636000.0 for Q1 2026.
- Quarterly Non-Current Assets rose 66.49% year-over-year to $636000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $636000.0 (up 66.49% YoY) and the FY2025 annual result came in at $695000.0, up 66.27% from the prior year.
- Non-Current Assets retreated to $636000.0 in Q1 2026, from $695000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $695000.0 in Q4 2025 and troughed at $233000.0 in Q1 2023.
- A 5-year average of $476352.9 and a median of $440000.0 in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 65.28% — and 2024, when it surged 109.44%.
- Tracing ENTX's Non-Current Assets over 5 years: stood at $278000.0 in 2022, then jumped by 82.73% to $508000.0 in 2023, then fell by 17.72% to $418000.0 in 2024, then jumped by 66.27% to $695000.0 in 2025, then decreased by 8.49% to $636000.0 in 2026.
- Business Quant data shows ENTX's Non-Current Assets at $636000.0 in Q1 2026, $695000.0 in Q4 2025, and $400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 39.71 Mn |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - | 636,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 636,000.00 |
| Dec 31, 2025 | 695,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 356,000.00 |
| Mar 31, 2025 | 382,000.00 |
| Dec 31, 2024 | 418,000.00 |
| Sep 30, 2024 | 401,000.00 |
| Jun 30, 2024 | 440,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Dec 31, 2023 | 508,000.00 |
| Sep 30, 2023 | 549,000.00 |
| Jun 30, 2023 | 631,000.00 |
| Mar 31, 2023 | 233,000.00 |
| Dec 31, 2022 | 278,000.00 |
| Sep 30, 2022 | 350,000.00 |
| Jun 30, 2022 | 662,000.00 |
| Mar 31, 2022 | 671,000.00 |
| Dec 31, 2021 | 658,000.00 |
| Dec 31, 2020 | 613,000.00 |
| Dec 31, 2018 | 875,000.00 |